ClinicalTrials.gg
CompletedNCT05283694Updated Mar 17, 2022

A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants

A Phase 1 interventional study of risankizumab and risankizumab in Healthy Volunteers, sponsored by AbbVie. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-17.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2018, 8 years 5 months ago, and no results have been posted to the registry.
  • Registered 4 years 5 months after the study started (first participant enrolled Sep 2017, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The objective of this study is to evaluate the bioavailability, safety and tolerability of risankizumab following subcutaneous injections in healthy male participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight less than 100.00 kg inclusive at Screening and Check-In Day.
  • (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2 after rounded to the tenths decimal, at Screening and upon confinement.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.
  • History of epilepsy, any cardiac, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Risankizumab Dose A

    Participants will receive 3 Subcutaneous (SC) injections of risankizumab Dose A administered via prepared syringe at Day 1 and followed for 140 days.

    Drug: risankizumab

  • Experimental
    Risankizumab Dose B

    Participants will receive 1 SC injection of risankizumab Dose B administered via syringe pump at Day 1 and followed for 140 days.

    Drug: risankizumab

  • Experimental
    Risankizumab Dose C

    Participants will receive 1 SC injection of risankizumab Dose C administered via syringe pump at Day 1 and followed for 140 days.

    Drug: risankizumab

  • Experimental
    Risankizumab Dose D

    Participants will receive 1 SC injection of risankizumab Dose D administered via prepared syringe at Day 1 and followed for 140 days.

    Drug: risankizumab

Interventions

  • Subcutaneous Injection via prepared syringe

    Also known as: ABBV-066, SKYRIZI

  • Subcutaneous Injection via syringe pump

    Also known as: ABBV-066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Maximum Observed Plasma Concentration

    Time frame: Up to 140 Days

  2. Time to maximum observed plasma concentration (Tmax)

    Time to maximum observed plasma concentration

    Time frame: Up to 140 Days

  3. Area under the plasma concentration-time curve (AUC) from time 0 to the time of last measurable concentration (AUCt)

    AUC from time 0 to the time of last measurable concentration

    Time frame: Up to 140 Days

  4. AUC from time 0 to infinity (AUCinf)

    AUC from time 0 to infinity

    Time frame: Up to 140 Days

  5. Terminal phase elimination rate constant (β)

    Terminal phase elimination rate constant

    Time frame: Up to 140 Days

  6. Terminal phase elimination half-life (t1/2).

    Terminal phase elimination half-life

    Time frame: Up to 140 Days

  7. Number of Anti-drug antibody (ADA) Titers

    Incidence of anti-drug antibodies

    Time frame: Up to 140 Days

  8. Number of Participants with Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

    Time frame: Up to 140 Days

07

Study locations

1 site
  • Acpru /Id# 165737
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Jun 2018, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2022
First posted
Mar 17, 2022
StartActual
Sep 11, 2017
Primary completionActual
Jun 12, 2018
CompletionActual
Jun 12, 2018
Last update
Mar 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05283694
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Sep 11, 2017
Primary completion
Jun 12, 2018
Completion
Jun 12, 2018
Last update
Mar 17, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion